Please ensure Javascript is enabled for purposes of website accessibility

Why Hims & Hers Health Fell by Nearly 11% Today

By Eric Volkman – Aug 16, 2021 at 5:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New week, new price target decrease from an analyst.

What happened

The stock of specialty telemedicine company Hims & Hers (HIMS -2.55%) took a big hit on Monday, cratering by 10.8%. It seems an analyst's modest price chop led to the investor sell-off.

So what

Early that morning, Credit Suisse prognosticator Jailendra Singh updated his price target on the stock, lowering it from $16 per share to $14. While doing so, however, he maintained his outperform (i.e., buy) recommendation.

That's still a very bullish outlook on Hims & Hers' potential. Even though it's been reduced, that price target is still nearly double the stock's current level. 

Doctor and patient conferring via tablet.

Image source: Getty Images.

Singh's slight revision comes two working days after Hims & Hers delivered impressive Q2 results with convincing beats on both the top and bottom lines, powered by revenue that increased nearly 70% on a year-over-year basis. The healthcare services company's 2021 revenue guidance was also well above expectations.

The Credit Suisse analyst isn't alone in becoming more cautious about the stock. In the wake of Thursday's earnings release, Piper Sandler's Sean Wieland also trimmed his price target on the shares, from $11 to $10, while keeping his neutral recommendation. He believes that while that guidance is realistic, he is concerned about the viability of Hims and Hers' strategy for international expansion.

Now what

Neither analysis is sounding serious alarm bells about the future of Hims & Hers, rather they are fairly minor adjustments to existing views. So this sell-off feels a bit melodramatic, and could therefore provide an opportunity for optimists to jump on the Hims & Hers train.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Hims & Hers Health, Inc. Stock Quote
Hims & Hers Health, Inc.
HIMS
$6.11 (-2.55%) $0.16
Credit Suisse Group Stock Quote
Credit Suisse Group
CS
$3.59 (-6.27%) $0.24
Piper Sandler Companies Stock Quote
Piper Sandler Companies
PIPR
$147.81 (0.49%) $0.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.